Pan-cancer analysis from GEPIA and TCGA databases demonstrates that elevated PDCL3 expression correlates with poorer outcomes in ACC, KICH, LGG, LUAD, LIHC, MESO, and UVM. Here, PDCL3 is linked to cancer.